Diagnostic Center | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The delegation's visit covered a wide range of topics
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Subscribe To Our Newsletter & Stay Updated
